About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Peanut Allergy Pipeline Market Insights Report 2025 | DBV712, PVX-108 & INP20 Lead the Way - ResearchAndMarkets.com

The "Peanut Allergy - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.

The "Peanut Allergy - Pipeline Insight, 2025" report delivers in-depth analysis of the Peanut Allergy therapeutic landscape, highlighting over 10 companies and upwards of 12 pipeline drugs.

This report encompasses detailed drug profiles across clinical and nonclinical stages, with assessments categorized by product type, stage, route of administration, and molecule type. Moreover, it touches on inactive pipeline products, providing a comprehensive view of the current scenario and future growth prospects in Peanut Allergy treatments.

Peanut allergy is a significant focus due to its prevalence and potential severity, often leading to severe reactions such as anaphylaxis. Although strict eradication of peanuts from the diet is advised, the pervasive presence of trace peanut residues makes total avoidance difficult, propelling the need for research toward innovative therapies. Immunotherapies and vaccine-based strategies are being developed to enhance tolerance and patient safety.

The report underscores groundbreaking therapies under development, including immunotherapy and vaccine strategies aimed at desensitizing the immune system. Notable drugs like DBV Technologies' DBV712 (in Phase III) target epicutaneous immunotherapy, offering a non-invasive daily treatment option. Aravax Pty Ltd's PVX-108, in Phase II, utilizes peptide sequences to retrain the immune system without requiring dose escalation, presenting a potential long-term solution with a low risk of severe reactions. InnoUp Farma S.L.'s INP20, currently in Phase I/II, leverages nanoparticle technology to provide controlled-release treatment directly to the gut, minimizing systemic absorption and reducing the risk of allergenic response.

The report thoroughly categorizes these drugs by various parameters such as product phase and route of administration, including oral, topical, and subcutaneous applications. Additionally, it segments according to molecule type, including recombinant fusion proteins, peptides, and gene therapies, reflecting the diverse approaches in addressing Peanut Allergy.

Furthermore, the report delves into detailed commercial and clinical assessments of the pipeline products, covering technology development, partnerships, licensing activities, and significant collaborations that could shape the future of Peanut Allergy therapeutics. Industry movements such as mergers, funding initiatives, and product development documents are also analyzed to present a full picture of the market dynamics.

Highlighted players in this space include DBV Technologies, Aravax Pty Ltd, and InnoUp Farma S.L., among others, advancing innovative solutions to meet the unmet needs in Peanut Allergy management. The report evaluates pipeline product profiles, therapeutic assessments, and the anticipated impact of emerging therapies, offering insights into the changing landscape of Peanut Allergy treatment.

Key questions addressed include the current number of drugs being developed, stages of development, partnerships shaping the industry, and recent technological advancements. The report positions itself as a robust resource for understanding the Peanut Allergy pipeline and prospective treatment modalities. As research progresses, the report promises regular updates on clinical studies, emerging trends, key collaborations, and market analyses impacting stakeholders in this field.

Key Topics Covered:

Introduction

Executive Summary

Peanut Allergy: Overview

  • Introduction
  • Causes
  • Pathophysiology
  • Signs and Symptoms
  • Diagnosis
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Peanut Allergy - Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

DBV712: DBV Technologies

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

PVX-108: Aravax Pty Ltd

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I/II)

  • Comparative Analysis

INP20: InnoUp Farma S.L.

  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Peanut Allergy Key Companies

Peanut Allergy Key Products

Peanut Allergy - Unmet Needs

Peanut Allergy - Market Drivers and Barriers

Peanut Allergy - Future Perspectives and Conclusion

Peanut Allergy Analyst Views

Peanut Allergy Key Companies

  • DBV Technologies
  • Aravax Pty Ltd
  • InnoUp Farma S.L.
  • Allergy Therapeutics
  • ALK-AbellA A/S
  • IgGenix Australia Pty Ltd

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/yxcynz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.